| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ... The Lancet 389 (10088), 2492-2502, 2017 | 3951 | 2017 |
| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1683* | 2020 |
| CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular … T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ... Annals of Oncology 30, v874-v875, 2019 | 737 | 2019 |
| Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma A Jusakul, I Cutcutache, CH Yong, JQ Lim, MN Huang, N Padmanabhan, ... Cancer discovery 7 (10), 1116-1135, 2017 | 722 | 2017 |
| Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ... Journal of Clinical Oncology 36 (3), 276, 2018 | 674 | 2018 |
| Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ... The Lancet Oncology 23 (1), 77-90, 2022 | 657 | 2022 |
| SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma PKH Chow, M Gandhi, SB Tan, MW Khin, A Khasbazar, J Ong, SP Choo, ... Journal of clinical oncology 36 (19), 1913-1921, 2018 | 598 | 2018 |
| Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers W Chan-On, ML Nairismägi, CK Ong, WK Lim, S Dima, C Pairojkul, ... Nature genetics 45 (12), 1474-1478, 2013 | 489 | 2013 |
| Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma AL Cheng, C Hsu, SL Chan, SP Choo, M Kudo Journal of hepatology 72 (2), 307-319, 2020 | 367 | 2020 |
| Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group G Ryan, G Martinelli, M Kuper-Hommel, R Tsang, G Pruneri, K Yuen, ... Annals of Oncology 19 (2), 233-241, 2008 | 326 | 2008 |
| Comparison of hepatocellular carcinoma in E astern versus W estern populations SP Choo, WL Tan, BKP Goh, WM Tai, AX Zhu Cancer 122 (22), 3430-3446, 2016 | 265 | 2016 |
| Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis T Yau, C Hsu, TY Kim, SP Choo, YK Kang, MM Hou, K Numata, W Yeo, ... Journal of Hepatology 71 (3), 543-552, 2019 | 215 | 2019 |
| A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements M Kudo, KH Han, SL Ye, J Zhou, YH Huang, SM Lin, CK Wang, M Ikeda, ... Liver cancer 9 (3), 245-260, 2020 | 213 | 2020 |
| First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma RD Kim, D Sarker, T Meyer, T Yau, T Macarulla, JW Park, SP Choo, ... Cancer discovery 9 (12), 1696-1707, 2019 | 193 | 2019 |
| RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma H Huynh, KH Pierce Chow, KC Soo, HC Toh, SP Choo, KF Foo, D Poon, ... Journal of cellular and molecular medicine 13 (7), 1371-1380, 2009 | 165 | 2009 |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative … LT Chen, E Martinelli, AL Cheng, G Pentheroudakis, S Qin, ... Annals of Oncology 31 (3), 334-351, 2020 | 156 | 2020 |
| CheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis M Kudo, A Matilla, A Santoro, I Melero, AC Gracián, M Acosta-Rivera, ... Journal of hepatology 75 (3), 600-609, 2021 | 155 | 2021 |
| Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma H Huynh, VC Ngo, HN Koong, D Poon, SP Choo, CH Thng, P Chow, ... Journal of cellular and molecular medicine 13 (8b), 2673-2683, 2009 | 148 | 2009 |
| The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma W Zhai, TKH Lim, T Zhang, ST Phang, Z Tiang, P Guan, MH Ng, JQ Lim, ... Nature communications 8 (1), 4565, 2017 | 136 | 2017 |
| Nivolumab (NIVO)+ ipilimumab (IPI)+ cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. T Yau, V Zagonel, A Santoro, M Acosta-Rivera, SP Choo, A Matilla, AR He, ... Journal of Clinical Oncology 38 (4_suppl), 478-478, 2020 | 123 | 2020 |
